Skip to main content
SpringerLink
Log in

Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions

  • Original Research Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Background

Large epidemiological databases facilitate the study of medical care in different subgroups of the population and how such care compares with standard treatment guidelines. This study aimed for such analyses regarding utilization of antiepileptic drugs (AEDs) for epilepsy in Germany.

Method

The data source was the Disease Analyzer® database that is representative for the German population and assembles anonymous demographic and medical (diagnoses, prescriptions) data obtained from the practice computer system of general practitioners and specialists throughout Germany. A total of 43,712 adult patients with an epilepsy diagnosis (International Classification of Diseases, 10th edition [ICD10] code: G40.X) seen in 2010–2012 by 346 neurologists were retrospectively analysed according to sociodemographic characteristics, comorbidity, and AED treatment. Multivariate logistic regression was applied to calculate adjusted odds ratios (ORs) with 95 % confidence intervals (CIs).

Results

As compared with women, men were less likely to receive lamotrigine (OR 0.68; 95 % CI 0.65–0.72; p < 0.001) and were treated preferably with carbamazepine (OR 1.29; 95 % CI 1.23–1.35; p < 0.001). As compared with patients covered by private health insurance (PHI), patients with statutory health insurance (SHI) were treated more often with valproate (OR 1.19; 95 % CI 1.07–1.31; p < 0.001) and showed a higher rate of obesity (SHI: 3.1 %; PHI: 1.6 %; p < 0.001), while PHI was associated with administration of levetiracetam (OR 1.27; 95 % CI 1.16–1.4; p < 0.001). Carbamazepine (OR 1.25; 95 % CI 1.17–1.31; p < 0.001) and primidone (OR 1.23; 95 % CI 1.08–1.38; p < 0.001) were administered to a larger extent in rural versus urban areas. Lamotrigine (OR 1.31; 95 % CI 1.23–1.39; p < 0.001) was used more often in West than in East Germany. Living in an urban community raised the likelihood of being treated with levetiracetam (OR 1.23; 95 % CI 1.17–1.28; p < 0.001).

Conclusions

In spite of common guidelines, AED treatment differed significantly among adults with epilepsy in Germany. Besides gender, type of health insurance and place of residence strongly influenced AED administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese JP, Schoffski O, et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults. J Neurol. 2012;259(11):2376–84.

    Article  PubMed  Google Scholar 

  2. Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav. 2013;27(3):433–8.

    Article  PubMed  Google Scholar 

  3. Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617–26.

    Article  CAS  PubMed  Google Scholar 

  4. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Meyer AC, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bul World Health Organ. 2010;88(4):260–6.

    Article  Google Scholar 

  6. Huber J, Mielck A. Morbidity and healthcare differences between insured in the statutory (“GKV”) and private health insurance (“PKV”) in Germany. Review of empirical studies. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010;53(9):925–38.

    Article  CAS  PubMed  Google Scholar 

  7. Odeyemi IA, Nixon J. The role and uptake of private health insurance in different health care systems: are there lessons for developing countries? Clinicoecon Outcomes Res. 2013;5:109–18.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Mattsson P, Tomson T, Eriksson O, Brannstrom L, Weitoft GR. Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients. Neurology. 2010;74(4):295–301.

    Article  CAS  PubMed  Google Scholar 

  9. Meyer AC, Dua T, Boscardin WJ, Escarce JJ, Saxena S, Birbeck GL. Critical determinants of the epilepsy treatment gap: a cross-national analysis in resource-limited settings. Epilepsia. 2012;53(12):2178–85.

    Article  PubMed  Google Scholar 

  10. Malmgren K, Flink R, Guekht AB, Michelucci R, Neville B, Pedersen B, et al. ILAE Commission of European Affairs Subcommission on European Guidelines 1998–2001: the provision of epilepsy care across Europe. Epilepsia. 2003;44(5):727–31.

    Article  PubMed  Google Scholar 

  11. Begley CE, Basu R, Reynolds T, Lairson DR, Dubinsky S, Newmark M, et al. Sociodemographic disparities in epilepsy care: results from the Houston/New York City health care use and outcomes study. Epilepsia. 2009;50(5):1040–50.

    Article  PubMed  Google Scholar 

  12. Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133–41.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012;344:e281.

    Article  PubMed  Google Scholar 

  14. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17.

    Article  CAS  PubMed  Google Scholar 

  15. Holden EW, Grossman E, Nguyen HT, Gunter MJ, Grebosky B, Von Worley A, et al. Developing a computer algorithm to identify epilepsy cases in managed care organizations. Dis Manag. 2005;8(1):1–14.

    Article  PubMed  Google Scholar 

  16. Schnusenberg O, Loh CP, Nihalani K. The role of financial wellbeing, sociopolitical attitude, self-interest, and lifestyle in one’s attitude toward social health insurance. Appl Health Econ Health Policy. 2013;11(4):369–81.

    Article  PubMed  Google Scholar 

Download references

Disclosures

The authors report the following possible sources of conflicts of interest.

Dr. Hamer has served on the scientific advisory board of cerbomed, Eisai, Pfizer, and UCB Pharma. He served on the speakers’ bureau of Cyberonics, Desitin, Eisai, GlaxoSmithKline, Novartis, and UCB Pharma and received research funding from Desitin, Janssen-Cilag, GlaxoSmithKline, and UCB Pharma.

K. Kostev is an employee of IMS HEALTH, a company that focuses on analysis of pharmacy records and runs the database used in this analysis. However, this study was not part of any business project.

No funding was received for the study or publication of the paper.

Author information

Authors and Affiliations

  1. Department of Neurology, Epilepsy Center, University of Erlangen, Schwabachanlage 6, 91054, Erlangen, Germany

    Hajo M. Hamer

  2. IMS HEALTH GmbH & Co. OHG, Epidemiology and Pharmacovigilance, Darmstädter Landstraße 108, 60598, Frankfurt am Main, Germany

    Karel Kostev

Authors
  1. Hajo M. Hamer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karel Kostev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hajo M. Hamer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamer, H.M., Kostev, K. Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions. CNS Drugs 28, 753–759 (2014). https://doi.org/10.1007/s40263-014-0187-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-014-0187-x

Keywords

Search

Navigation